Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30819926

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2019 May 2
First author
Facon T

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Facon T
      type
      Author
    2. name
      Lee JH
      type
      Author
    3. name
      Moreau P
      type
      Author
    4. name
      Niesvizky R
      type
      Author
    5. name
      Dimopoulos M
      type
      Author
    6. name
      Hajek R
      type
      Author
    7. name
      Pour L
      type
      Author
    8. name
      Jurczyszyn A
      type
      Author
    9. name
      Qiu L
      type
      Author
    10. name
      Klippel Z
      type
      Author
    11. name
      Zahlten-Kumeli A
      type
      Author
    12. name
      Osman M
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Facon T
      type
      Author
    2. name
      Lee JH
      type
      Author
    3. name
      Moreau P
      type
      Author
    4. name
      Niesvizky R
      type
      Author
    5. name
      Dimopoulos M
      type
      Author
    6. name
      Hajek R
      type
      Author
    7. name
      Pour L
      type
      Author
    8. name
      Jurczyszyn A
      type
      Author
    9. name
      Qiu L
      type
      Author
    10. name
      Klippel Z
      type
      Author
    11. name
      Zahlten-Kumeli A
      type
      Author
    12. name
      Osman M
      type
      Author
    bibliography ids
    1. nci-bib-be6ab5b03901f77bb7f1a708
    book metadata
    content sha256
    5e4cd2890e3735f4548cbf76f62cb205f58255b1736447d166199a88221cef98
    document type
    citation
    dois
    1. 10.1182/blood-2018-09-874396
    electronic publication date
    display
    2019 Feb 28
    precision
    day
    year
    2019
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:30819926
    immutable id
    pubmed:30819926@5e4cd2890e3735f4548cbf76f62cb205f58255b1736447d166199a88221cef98
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    18
    name
    Blood
    nlm unique id
    7603509
    pages
    1953-1963
    volume
    133
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      30819926
      provenance
      batch id
      e808962322f3afebc564
      provider
      NCBI PubMed ESummary
      record sha256
      3a3e9db537fdc3d460d8a1c9727beaf80ffae4071b625b6176da8ec7bec57687
      response sha256
      3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
      retrieved at
      2026-09-09T23:47:41.002093+00:00
      publication date
      display
      2019 May 2
      precision
      day
      year
      2019
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/30819926/
      title
      Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

      Preserved source evidence · Not medical advice